Christmas Cheer For Daiichi, Another Win Vs Ranbaxy Brothers
Executive Summary
Daiichi Sankyo has secured another favorable ruling in Singapore in a case pertaining to the enforcement of the INR35bn arbitration award against the sparring Singh brothers of Ranbaxy, piling more pressure on the duo. An appeal remains an option.
You may also be interested in...
From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo
When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company?
India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
All Downhill: Ranbaxy Singh Brothers Trade Charges, Blows
The Singh brothers' feud has moved from a war of words allegedly to blows, with any efforts at reconciliation looking bleak. The siblings also find themselves in tight spot as Daiichi Sankyo presses ahead to enforce a INR35bn damages award.